Journal of Thoracic Oncology最新文献

{"title":"Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report","authors":"Daniele Tavernari PhD ,&nbsp;Maxime Borgeaud MD ,&nbsp;Ximeng Liu PhD ,&nbsp;Kaushal Parikh MD ,&nbsp;Xiuning Le MD, PhD ,&nbsp;Giovanni Ciriello PhD ,&nbsp;Alfredo Addeo MD","doi":"10.1016/j.jtho.2024.12.012","DOIUrl":"10.1016/j.jtho.2024.12.012","url":null,"abstract":"<div><h3>Introduction</h3><div>EGFR mutations are key oncogenic drivers in lung adenocarcinoma (LUAD), predominantly affecting Asian, nonsmoking, and female populations. Although common mutations, such as exon 19 deletions and L858R, respond well to tyrosine kinase inhibitors (TKIs), uncommon EGFR mutations and compound variants exhibit variable treatment responses. This study aims to compare clinical characteristics and molecular profiles of patients with common, uncommon, and compound EGFR mutations, assessing their implications for therapy outcomes.</div></div><div><h3>Methods</h3><div>We analyzed a multi-cohort genomic dataset of 19,163 patients with LUAD (5,212 with EGFR mutations), categorizing mutations into common, uncommon, and compound classes. Patient demographics, mutational signatures, and tumor microenvironment factors were assessed, with particular attention to smoking status and concomitant alterations in KRAS and TP53. Treatment outcomes were analyzed by time under treatment as a surrogate measure of TKI efficacy.</div></div><div><h3>Results</h3><div>Uncommon EGFR mutations, comprising 8.9% of EGFR-altered cases, were significantly more frequent among smokers and associated with tobacco-related mutational signatures. Compared with common EGFR-mutant cases, tumors harboring uncommon EGFR mutations reported higher rates of EGFR amplifications, KRAS, and TP53 mutations. Uncommon mutations also exhibited higher tumor mutational burden and distinct transcriptional profiles linked to cell cycle activity. Median time on treatment with TKIs was notably shorter in patients with uncommon mutations (4.1 mo) than those with common and compound mutations (10.9 mo and 12.4 mo, respectively).</div></div><div><h3>Conclusions</h3><div>This study underscores the clinical and molecular heterogeneity of EGFR mutation classes in LUAD, highlighting the unique profile of uncommon mutations, particularly their association with smoking and co-mutations in KRAS and TP53. Comprehensive molecular testing, including next-generation sequencing, is crucial to identify these uncommon mutations and inform therapeutic decisions. Further investigation into the role of immunotherapy in patients with uncommon EGFR mutations is warranted given the tobacco-related molecular signatures and high tumor mutational burden associated with this subgroup.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages 500-506"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OA07.01 KRAS Pharmacological Blockade Elicits Tumoral Homologous Recombination Deficiency Exploitable With PARP Inhibitors","authors":"Connor Welch ,&nbsp;Gabriela Novoa ,&nbsp;Alba Santos ,&nbsp;Carlos Vasquez ,&nbsp;Alejandra Lagos ,&nbsp;Iker Feliu ,&nbsp;Irati Macaya ,&nbsp;Nerea Bakartxo ,&nbsp;Rosario Prados-Carvajal ,&nbsp;Alberto Sogari ,&nbsp;Pablo Huertas ,&nbsp;Alfonso Calvo ,&nbsp;Elizabeth Guruceaga ,&nbsp;Luis Paz-Ares ,&nbsp;Alberto Bardelli ,&nbsp;Mariangela Russo ,&nbsp;Irene Ferrer ,&nbsp;Silve Vicent","doi":"10.1016/j.jtho.2025.03.008","DOIUrl":"10.1016/j.jtho.2025.03.008","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page S2"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP01.10 Dual Targeting of RET and SRC to Treat RET-Positive Non-Small Cell Lung Cancer","authors":"Juhyeon Son ,&nbsp;Lily L. Remsing Rix ,&nbsp;Bin Fang ,&nbsp;Eric A. Welsh ,&nbsp;Alexander Drilon ,&nbsp;John M. Koomen ,&nbsp;Emiliano Cocco ,&nbsp;Uwe Rix","doi":"10.1016/j.jtho.2025.03.018","DOIUrl":"10.1016/j.jtho.2025.03.018","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page S7"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Board of Directors","authors":"","doi":"10.1016/S1556-0864(25)00077-2","DOIUrl":"10.1016/S1556-0864(25)00077-2","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page A3"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143785083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distant Cousins From the Same Family—Understanding Uncommon EGFR Mutations","authors":"Stephanie P.L. Saw M.B.B.S., MMed, MRCP ,&nbsp;Molly S.C. Li M.B.B.S., MRCP","doi":"10.1016/j.jtho.2025.01.007","DOIUrl":"10.1016/j.jtho.2025.01.007","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages 415-418"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143785089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ‘The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer’ [Journal of Thoracic Oncology, Volume 19 Issue 5 (2024) 786-802]","authors":"Kwun M. Fong M.B.B.S., PhD ,&nbsp;Adam Rosenthal MS ,&nbsp;Dorothy J. Giroux MS ,&nbsp;Katherine K. Nishimura PhD, MPH ,&nbsp;Jeremy Erasmus MD ,&nbsp;Yolande Lievens MD, PhD ,&nbsp;Mirella Marino MD ,&nbsp;Edith M. Marom MD ,&nbsp;Paul Martin Putora MD, PhD ,&nbsp;Navneet Singh MD, DM, FRCP ,&nbsp;Francisco Suárez MD ,&nbsp;Ramon Rami-Porta MD ,&nbsp;Frank Detterbeck MD ,&nbsp;Wilfried E.E. Eberhardt Priv.-Doz. ∗ ,&nbsp;Hisao Asamura MD ∗ ,&nbsp;Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Members of the Advisory Boards, and Participating Institutions of the Lung Cancer Domain","doi":"10.1016/j.jtho.2025.01.017","DOIUrl":"10.1016/j.jtho.2025.01.017","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page 531"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brief Report: Evaluating Early Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening","authors":"Matthew T. Warkentin PhD ,&nbsp;Martin C. Tammemägi PhD ,&nbsp;Erik Vakil MD ,&nbsp;Eric L.R. Bedard MD ,&nbsp;Winson Y. Cheung MD ,&nbsp;Darren R. Brenner PhD ,&nbsp;Alain Tremblay MDCM","doi":"10.1016/j.jtho.2024.12.025","DOIUrl":"10.1016/j.jtho.2024.12.025","url":null,"abstract":"<div><h3>Introduction</h3><div>Older individuals have an elevated lung cancer risk but may also have substantial comorbidities that preclude curative treatment options and limit the survival benefits of screening. The objective of this study was to assess early stage lung cancer survival patterns among those at the upper age limit for screening and identify older individuals who have the potential to benefit from lung cancer screening.</div></div><div><h3>Methods</h3><div>We identified all early stage (I or II) lung cancers diagnosed in Alberta, Canada between 2010 and 2020. Overall survival (OS) was based on the time from the date of lung cancer diagnosis to the date of death (from any cause) or censoring. We estimated OS using the Kaplan-Meier method. We present OS with 95% confidence intervals (CIs) for each age group and sex and stratified by presence of comorbidities (Charlson Comorbidity Index) and receipt of surgery.</div></div><div><h3>Results</h3><div>There were 6401 early stage lung cancers (71% stage I, 29% stage II), of which 43% and 57% were among males and females, respectively. For females, the 5-year OS was 54.7% (95% CI: 50.6–58.8), 47.2% (95% CI: 42.7–51.7), and 33.7% (95% CI: 28.4–38.9) for ages 70 to 74 years, 75 to 79 years, and 80 to 84 years, respectively. For males, the 5-year OS was 47.7% (95% CI: 43.1–52.3), 38.0% (95% CI: 33.2–42.8), and 24.2% (95% CI: 19.2–29.3) for ages 70 to 74 years, 75 to 79 years, and 80 to 84 years, respectively. Across all age groups, the 5-year OS was higher for those with fewer comorbidities and for those who received surgery as part of their treatment strategy, usually surpassing that in younger cohorts with more comorbidities or those who did not receive surgical treatment.</div></div><div><h3>Conclusions</h3><div>Age limits for lung cancer screening should consider comorbidity and fitness for curative treatment because these can significantly influence the survival after diagnosis and treatment of early lung cancer.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages 507-512"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing the Implementation of Risk Model-Based Lung Cancer Screening","authors":"Yeon Wook Kim MD, PhD ,&nbsp;Choon-Taek Lee MD, PhD","doi":"10.1016/j.jtho.2025.01.008","DOIUrl":"10.1016/j.jtho.2025.01.008","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages 419-421"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143785090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Horizons in Lung Cancer Screening: Eligibility Criteria, Risk Models, and Emerging Challenges","authors":"Mattia Boeri PhD ,&nbsp;Anna Zanghì MSc ,&nbsp;Ugo Pastorino MD","doi":"10.1016/j.jtho.2025.01.021","DOIUrl":"10.1016/j.jtho.2025.01.021","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages 422-424"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143785091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OA03.01 Unveiling the Anti-Tumor Activity of Exarafenib in BRAF-Mutated NSCLC Through Genomic Analysis and Combined Preclinical, Clinical Outcomes","authors":"Tadashi Manabe ,&nbsp;Tim Sen Wang ,&nbsp;Paul Severson ,&nbsp;Nichol Miller ,&nbsp;Catherine Lee ,&nbsp;Elifnur Yay Donderici ,&nbsp;Nicole Zhang ,&nbsp;Hannah C. Bergo ,&nbsp;Yu-ting Chou ,&nbsp;Daniel L. Kerr ,&nbsp;Wei Wu ,&nbsp;Kathryn B. Grandinetti ,&nbsp;Liliana Soroceanu ,&nbsp;Robert J. Pelham ,&nbsp;Eric S. Martin ,&nbsp;Eric A. Murphy ,&nbsp;Vishesh Khanna ,&nbsp;Joel W. Neal ,&nbsp;Christopher T. Chen ,&nbsp;Shumei Kato ,&nbsp;Trever G. Bivona","doi":"10.1016/j.jtho.2025.03.006","DOIUrl":"10.1016/j.jtho.2025.03.006","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages S1-S2"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}